We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Staging cutaneous squamous cell carcinoma in an Irish cohort.
- Authors
Doyle, Claire; Drumm, Ciara; Hellen, Rebecca; McKay, Hannah; D'Arcy, Clare; Lally, Aoife; Moriarty, Blaithin
- Abstract
Staging the cSCC of those patients who developed recurrent or progressive disease revealed that 62.1% (18/29) were AJCC T1, 3.4% (1/29) were T2 and 34.4% (10/29) were T3. The AJCC system classified 61% (416/682) of tumours as tumour stage 1 (T1), 15.2% (104/682) as T2, 23.6% (161/682) as T3 and 0.1% (1/682) as T4. Https://doi.org/10.1093/ced/llac135 Dear Editor, Staging systems currently in use for cutaneous squamous cell carcinoma (cSCC) are poor at quantifying the risk of both local recurrence and distant metastases.[1] High-risk prognostic features include tumour diameter (>= 2 cm), depth of invasion (>= 6 mm), tumour site (ear and lip), poorly differentiated tumours, lymphovascular invasion, perineural invasion and host immunosuppression.[2],[3] Staging systems in use include the Brigham and Women's Hospital (BWH), the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC), none of which are validated for cSCC in Ireland.[4] It has been indicated that the BWH is more accurate than both the AJCC and the UICC staging systems at predicting both local tumour progression and distant metastases.[1] We report our experience in an Irish cohort.
- Subjects
SQUAMOUS cell carcinoma; INFORMED consent (Medical law)
- Publication
Clinical & Experimental Dermatology, 2023, Vol 48, Issue 4, p405
- ISSN
0307-6938
- Publication type
Article
- DOI
10.1093/ced/llac135